UPDATE: Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research
Rating reports today from Deutsche Bank includes analyst Alethia Young initiating coverage on Arrowhead Research (NASDAQ: ARWR). The initial rating is a Buy with a price target of $45.
Young notes, "Arrowhead is an early stage platform company that we believe could have the market cap potential of $4-5B as it becomes de-risked. The company's lead target is ARC-520 for Hepatitis B (HBV). Our HBV deep dive suggests ARC-520 could grow the market from $2B to $5B and see $5.2B peak sales WW."
Some risks that were mentioned includes possible safety and efficacy issues relating to drug and platform technology. Possible clinical delays on ARC-520 may also hinder then ability of ARWR to reach its potential.
ARWR closed previous trading session at $21.14 and is currently trading around the $25.23 mark, up over 19%. The price target of $45 displays a 170% upside from current trading prices.
Latest Ratings for ARWR
|Jan 2015||Deutsche Bank||Downgrades||Buy||Hold|
|Oct 2014||RBC Capital||Downgrades||Outperform||Sector Perform|
|Oct 2014||Deutsche Bank||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.